Myricx Pharma
Develops antibody-drug conjugate cancer therapies using payloads based on N-myristoyltransferase inhibitors
Highlights
- New on EvolcAdded 2026-10-31
About Myricx Pharma
Myricx Bio discovers and develops antibody-drug conjugates (ADCs) using cytotoxic payloads based on inhibitors of N-myristoyltransferases. Its pipeline targets cancer, including solid tumours.
The company is headquartered in London and operates from office and laboratory facilities at the London Innovation Centre. Myricx Bio is a trading name of Myricx Pharma Limited and became an indirect, wholly owned subsidiary of Novartis AG on August 28, 2026.
Product: A pipeline of antibody-drug conjugates using N-myristoyltransferase inhibitor payloads for cancer treatment.
Jobs at Myricx Pharma
More biotech & pharma companies
Neurolieve Biosciences
Developing a non-opioid biologic for patients with neuropathic pain, designed to relieve pain and support nerve regenerationYoung companyNew on EvolcNexus Bioquest
Immunology CRO running custom assays and pre-clinical drug discovery studies for pharma and biotech teamsYoung companyNew on EvolcNonacus
Liquid biopsy NGS panels and kits for cancer detection and monitoring, sold to clinical labs, hospitals and researchersNew on EvolcNorgine
Specialist pharmaceutical company acquiring, developing and commercialising medicines for gastroenterology and other therapy areas in EuropeNorthumbria Pharma
Develops and supplies pharmaceutical products and licensing, regulatory and safety services for healthcare and pharmaceutical partnersNew on EvolcNovabiotics
Clinical-stage biotech with cysteamine drug candidates and a nail-care product sold through UK podiatristsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- WordPress
- jQuery